Novo Nordisk A/S (NYSE:NVO) Shares Sold by Dynasty Wealth Management LLC

Dynasty Wealth Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 10.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 10,546 shares of the company’s stock after selling 1,214 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $907,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. DAVENPORT & Co LLC raised its stake in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock worth $90,477,000 after purchasing an additional 451,641 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,017,000. DSM Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock worth $172,678,000 after buying an additional 286,912 shares during the last quarter. World Investment Advisors LLC raised its position in shares of Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock valued at $33,388,000 after buying an additional 270,234 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Novo Nordisk A/S by 53.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 729,965 shares of the company’s stock valued at $63,183,000 after acquiring an additional 254,475 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock opened at $90.68 on Friday. The business’s fifty day moving average price is $84.82 and its 200 day moving average price is $106.90. Novo Nordisk A/S has a 12-month low of $77.82 and a 12-month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $406.91 billion, a PE ratio of 27.56, a P/E/G ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.